ESTRO meets Asia 2024 - Abstract Book

S85

Interdisciplinary – Breast

ESTRO meets Asia

Material/Methods:

This study is a prospective pilot study, where 15 patients of early breast cancer treated with UHFRT. All patients received 26 Gy radiation in 5 fractions. Two patients received 10 Gy boost to tumor cavity. All of them treated with 3-dimensional conformal (3DCRT) technique. All patients had right sided breast cancer. Patients were followed up during radiotherapy, 2 weeks and 1.5 months after radiotherapy.

Results:

The median age of the patients was 50 years. Most of the patients had T 2 disease (73.33%) , rest had T 1 disease. The number of node positive patients were 60% (N 1 ) and 40% patients were node negative. About 46.66 % patients had high grade disease. Percentage of triple negative and her 2 positive ceases were 40%. No patients had skin toxicity during radiotherapy but almost all patients had RTOG grade 1 skin toxicity at week 5 th week follow up. Only 2 patients developed RTOG grade 2 skin toxicity. No pharyngeal toxicity is seen.

Conclusion:

UHFRT is a well-tolerated radiation protocol for early stage breast cancer patient with acceptable toxicity. More over UHFRT takes less machine time and has cost benefit for patients. So, a limited radiation facility country like Bangladesh can adapt it in larger scale.

Keywords: Early breast cancer, Ultra Hypofractionated RT

References:

1.Global Cancer Statistics 2020:

2.Ahsania Mission Cancer registry 2023

3. Pathak, R., Sarin, R., Wadasadawala, T., Krishnamurthy, R., Karmakar, S. and Khandavalli, A., 2023. Largest real world data of regional nodal irradiation using ultra-hypofractionated 5-fraction adjuvant radiation therapy for breast cancer from a single institute in India. International Journal of Radiation Oncology, Biology, Physics , 117 (2), p.S7. 4. Brunt, A.M., Haviland, J.S., Wheatley, D.A., Sydenham, M.A., Alhasso, A., Bloomfield, D.J., Chan, C., Churn, M., Cleator, S., Coles, C.E. and Goodman, A., 2020. Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial. The Lancet , 395 (10237), pp.1613-1626. 5. Mohanapriya, A., Patro, K.C., Padhi, S., Kundu, C., Bhattacharyya, P.S., Pilaka, V.K.R., Rao, M.M., Prabu, A.C., Kumar, A.A., Aketi, S. and Prasad, P., 2022. FAST-Forward trial in breast cancer: a prospective pilot study addressing dosimetric and practice feasibility in Indian scenario. Journal of Current Oncology , 5 (1), p.8. 6. Giridhar, P., Pradhan, S., Pujari, L., Singh, P., Shinghal, A., Khandelwal, C., Mukherjee, C., Tripathi, M., Shukla, V., Manikandan, M.V. and Choudary, Z., 2023. Is FAST FORWARD the Way Forward in Radiotherapy for Locally Advanced Breast Cancer–Learnings From the COVID Pandemic. Clinical Breast Cancer .